Skip to main content

Displaying 2721 - 2740 of 4737

Nov07

100th Anniversary Symposium

For 100 years, the Federal Trade Commission has distinguished itself as a unique and nimble institution. The FTC continually evolves and innovates to promote competition and protect consumers. Please...

Prestige Brands Holdings, Inc. and Insight Pharmaceuticals Corporation, In the Matter of

Pharmaceutical company Prestige Brands Holdings, Inc., the maker of Dramamine, agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle FTC charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige proposed to acquire Insight for $750 million. According to the FTC’s complaint, Prestige’s Dramamine, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs, and Insight’s Bonine, are the only two branded products with significant sales. Absent a remedy, the acquisition would eliminate the close competition between Dramamine and Bonine, likely leading to higher prices for consumers.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
141 0159